Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.9K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Virome-wide ubiquitin ligase discovery reveals diverse mechanisms of immune evasion.

Science (New York, N.Y.)·2026
Same author

ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.

Journal for immunotherapy of cancer·2026
Same author

A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.

Cell reports. Medicine·2026
Same author

Reduced Myocardial Serine Synthesis Impairs Functional, Metabolic, and Redox Adaptations to Cardiac Stress.

bioRxiv : the preprint server for biology·2026
Same author

Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

The SLC25A45-TML Axis as a Biological Foundation for a Multivariable Plasma Metabolite Signature for High-Precision Prostate Cancer Detection.

Cancers·2026

関連する実験動画

Updated: May 2, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.2K

エンジニアリングされたIL-2部分アゴニストは,CD8+ T細胞幹細胞性を促進する

Fei Mo1, Zhiya Yu2, Peng Li1

  • 1Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Nature
|September 16, 2021
PubMed
まとめ

エンジニアリングされたサイトカインであるH9Tは,末端の分化を引き起こすことなく,がん免疫療法のためのCD8+T細胞を拡張します. このアプローチは幹細胞のような状態を維持し,臨床前モデルの抗腫瘍活性を強化します.

さらに関連する動画

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K
Generation of Natural Killer Cells from Human Expanded Potential Stem Cells
06:53

Generation of Natural Killer Cells from Human Expanded Potential Stem Cells

Published on: January 13, 2023

3.3K

関連する実験動画

Last Updated: May 2, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K
Generation of Natural Killer Cells from Human Expanded Potential Stem Cells
06:53

Generation of Natural Killer Cells from Human Expanded Potential Stem Cells

Published on: January 13, 2023

3.3K

科学分野:

  • 免疫学
  • 分子生物学
  • バイオテクノロジー

背景:

  • アドプティブT細胞移植は 癌の免疫療法における 重要な戦略です
  • T細胞数と分化状態は治療効果に重大な影響を及ぼします.
  • 標準的なT細胞拡張方法は,末端の分化と有効性の低下につながる可能性があります.

研究 の 目的:

  • CD8+ T細胞の膨張と分化に作用するH9Tという人工インタールキン-2部分アゴニストを調査する.
  • 改善された免疫療法のために,H9TがT細胞で幹細胞のような状態を維持できるかどうかを判断する.
  • 臨床前がんモデルにおけるH9T拡張型T細胞の治療可能性を評価する.

主な方法:

  • T細胞の拡張のために,H9T,エンジニアリングされたインタールイキン-2の部分的アゴニストを使用した.
  • STAT5信号,転写,表遺伝,そして代謝の変化を分析した.
  • T細胞転写因子1 (TCF-1) 発現とミトコンドリアフィットネスの評価
  • マウスモデルにおけるH9T拡張型T細胞の評価された抗腫瘍活性.

主要な成果:

  • H9Tは端末の分化を促すことなくCD8+T細胞の拡大を促した.
  • 明確な下流転写,表遺伝,代謝プログラムが観察されました.
  • H9TはTCF-1の発現を継続し,ミトコンドリアの健康状態を向上させ,幹細胞のような状態を維持した.
  • H9T拡張したTCR- トランスジェニックおよびCAR- 改変されたT細胞は,体内で強力な抗腫瘍活性を示した.

結論:

  • H9Tのような 設計されたサイトカインの変種は T細胞ベースのがん免疫療法を 強化する有望な戦略です
  • H9Tは幹細胞のような機能的なCD8+T細胞の拡張を促進する.
  • このアプローチは,新しい免疫療法薬の開発に翻訳的可能性を秘めています.